Asymmetric dimethylarginine in hemodialysis, hemodiafiltration, and peritoneal dialysis.

Asymmetric dimethylarginine (ADMA) is a mediator of endothelial dysfunction. Production and elimination of ADMA may be affected by the type of renal replacement therapy used and oxidative stress. Plasma ADMA, advanced glycation end products (AGE), and homocysteine were assessed in 59 subjects: 20 hemodialysis (HD) patients, 19 patients undergoing peritoneal dialysis (PD), and 20 controls. Results were compared between the groups. The effect of 8 weeks of HD and high-volume predilution hemodiafiltration (HDF) was compared in a randomized study. HD patients showed higher ADMA (1.20 [0.90-1.39 micromol/L]) compared to controls (0.89 [0.77-0.98], P < 0.01), while ADMA in PD did not differ from controls (0.96 [0.88-1.28]). AGE and homocysteine were highest in HD, lower in PD (P < 0.01 vs. HD), and lowest in controls (P < 0.001 vs. HD and PD). PD patients had higher residual renal function than HD (P < 0.01). The decrease in ADMA at the end of HD (from 1.25 [0.97-1.33] to 0.66 [0.57-0.73], P < 0.001) was comparable to that of HDF. Switching from HD to HDF led to a decrease in predialysis homocysteine level in 8 weeks (P < 0.05), while ADMA and AGE did not change. Increased ADMA levels in patients undergoing HD, as compared to PD, may be caused by higher oxidative stress and lower residual renal function in HD. Other factors, such as diabetes and statin therapy, may also be at play. The decrease in ADMA at the end of HD and HDF is comparable. Switching from HD to HDF decreases in 8 weeks the predialysis levels of homocysteine without affecting ADMA.

[1]  J. Warren,et al.  Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  P. Tsao,et al.  Asymmetrical Dimethylarginine in Renal Disease: Limits of Variation or Variation Limits? , 2007, American Journal of Nephrology.

[3]  R. Cibulka,et al.  Asymmetric dimethylarginine--comparison of HPLC and ELISA methods. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  T. Zima,et al.  No Benefit of Hemodiafiltration over Hemodialysis in Lowering Elevated Levels of Asymmetric Dimethylarginine in ESRD Patients , 2006, Blood Purification.

[5]  H. Makino,et al.  Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  K. Leunissen,et al.  Pre-dilution on-line haemofiltration vs low-flux haemodialysis: a randomized prospective study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  A. Santoro,et al.  Procalcitonin as a marker of micro-inflammation in hemodialysis. , 2005, Journal of nephrology.

[8]  S. Lentz,et al.  ADMA and hyperhomocysteinemia , 2005, Vascular medicine.

[9]  C. Zoccali,et al.  Clinical Epidemiology of Major Nontraditional Risk Factors in Peritoneal Dialysis Patients , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[10]  K. Kalantar-Zadeh,et al.  Reverse Epidemiology: A Spurious Hypothesis or a Hardcore Reality? , 2004, Blood Purification.

[11]  H. Arnesen,et al.  Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. , 2004, Metabolism: clinical and experimental.

[12]  D. Fliser,et al.  Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. , 2004, Clinical nephrology.

[13]  W. Sheu,et al.  Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. , 2004, The American journal of cardiology.

[14]  T. Münzel,et al.  ADMA and oxidative stress. , 2003, Atherosclerosis. Supplements.

[15]  P. Vallance,et al.  Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[16]  C. Zoccali,et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.

[17]  P. Tsao,et al.  Homocysteine Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine , 2001, Circulation.

[18]  M. Denton,et al.  Dimethylarginines in chronic renal failure , 2001, Journal of clinical pathology.

[19]  D. Tsikas,et al.  LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. , 2000, Circulation research.

[20]  Y. Wada,et al.  Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. , 1997, Kidney international.

[21]  V. Monnier,et al.  Chromatographic Quantitation of Plasma and Erythrocyte Pentosidine in Diabetic and Uremic Subjects , 1992, Diabetes.

[22]  J. Twisk,et al.  Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  B. Horne,et al.  Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk? , 2007, American heart journal.

[24]  C. Zoccali,et al.  The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  D. Marcelli,et al.  Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  P. Riederer,et al.  Determination of Advanced Glycation End Products in Serum by Fluorescence Spectroscopy and Competitive ELISA , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.